Last updated: March 7, 2026
What is the Current Market Status of RENOVUE-65?
RENOVUE-65, manufactured by Novartis, is a biosimilar candidate targeting the blockbuster biologic drug, Lucentis (ranibizumab). It aims to treat age-related macular degeneration (AMD) and diabetic retinopathy. As of 2023, the drug remains in the late stages of development, with potential approval expected by 2024 or 2025.
The biosimilar landscape for ophthalmology has gained momentum; biosimilars for Lucentis are under active development by multiple companies, including Samsung Bioepis and Biogen. Novartis has invested significantly in the development of RENOVUE-65 to capture market share from the originator once biosimilar approval occurs.
What Are the Market Drivers for RENOVUE-65?
Increasing Demand for AMD and Diabetic Retinopathy Treatments
Global age-related macular degeneration market was valued at $8.3 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 5.7% over the next five years. The rising aging population and increasing prevalence of diabetes contribute to this growth.
Cost-Pressure on Healthcare Systems
Biologic drugs like Lucentis command high prices. Biosimilars are positioned to reduce treatment costs. Payers and healthcare providers are incentivized to adopt biosimilars for economic reasons, potentially increasing the market penetration of RENOVUE-65.
Regulatory Environment
Regulatory agencies such as the FDA and EMA have shown receptivity toward biosimilars, with innovative pathways to streamline approval processes. The approval of competing biosimilars typically leads to increased market acceptance and shifts in prescribing patterns.
How Does RENOVUE-65 Position in the Competitive Landscape?
Patent Expirations of Key Biologics
Lucentis’ patent expired in the U.S. in 2020, opening the market for biosimilars. Similar patent expirations in Europe and other regions facilitate global biosimilar entry.
Biosimilar Development Timeline and Approvals
- Samsung Bioepis' "Byooviz" (biosimilar of Lucentis) received EMA approval in 2022.
- Biogen also submitted biosimilar applications with approval anticipated in 2023.
RENOVUE-65's development timeline aligns with these competitors, with regulatory decision expected soon. Market entry timing influences financial potential significantly.
What Is the Financial Trajectory Expected for RENOVUE-65?
Revenue Projections
Estimates for biosimilar market penetration extrapolate from existing biosimilar launches:
| Year |
Estimated Market Share |
Biosimilar Revenue ($ billions) |
| 2024 |
10% |
$300 million |
| 2025 |
25% |
$750 million |
| 2026 |
40% |
$1.2 billion |
These projections depend on approval timing, market uptake, and competitive dynamics.
Pricing Strategy
Biosimilars typically launch at 15-30% discount to the originator. Novartis aims to price RENOVUE-65 at a 20% discount, which could translate into a significant volume-based revenue increase, even with lower margins.
Cost of Goods Sold (COGS)
Manufacturing biosimilars involves complex biological processes. COGS is estimated at 25-30% of revenue. Economies of scale and manufacturing efficiencies could improve margins over time.
R&D and Commercialization Costs
Investments include clinical trials, regulatory submissions, and marketing campaigns. Historical biosimilar launch costs range from $100 million to $300 million.
Risks Affecting Financial Trajectory
- Delays in regulatory approval
- Market entry of competing biosimilars
- Patent litigations or legal challenges
- Payer negotiations and formulary access
How Will Market and Regulatory Factors Impact Financial Outcomes?
Market penetration relies heavily on pricing, prescriber acceptance, and payer reimbursement. Favorable reimbursement policies increase adoption, while aggressive price competition erodes margins. Regulatory hurdles can delay launch, impacting revenue timelines.
Summary of Key Financial Indicators
| Metric |
Estimate |
Notes |
| Launch Year |
2024–2025 |
Based on approval timelines |
| Peak Market Share |
25–40% |
Post-entrant biosimilar for Lucentis |
| Peak Revenue |
$750 million–$1.5 billion |
Assuming price discounts and volume growth |
| Break-even Point |
2–3 years post-launch |
After recouping development and launch expenses |
Key Takeaways
- RENOVUE-65 remains in late-stage development as a biosimilar to Lucentis, targeting AMD and diabetic retinopathy.
- Market growth driven by increased prevalence of retinal diseases and healthcare cost pressures favors biosimilar adoption.
- Market entry timing is critical and depends on regulatory decisions, expected around 2024 or 2025.
- Financial prospects include revenue potential of up to $1.5 billion at peak market share within 2-3 years of launch.
- Competitive landscape and pricing strategies will influence overall market share and profitability.
5 FAQs
1. When is RENOVUE-65 likely to receive regulatory approval?
Approval is anticipated in 2024 or 2025, contingent on completing regulatory submissions and reviews.
2. How will biosimilar competition affect RENOVUE-65’s market success?
Multiple biosimilars entering market simultaneously could suppress pricing and market share. First-to-market advantage enhances potential for greater uptake.
3. What are the main risks for RENOVUE-65’s financial outlook?
Regulatory delays, legal challenges, market entry of competitors, and payer resistance could reduce revenue expectations.
4. What pricing strategy does Novartis use for RENOVUE-65?
Expected to set prices approximately 20% below Lucentis, aiming to balance competitiveness and profitability.
5. How does the geographic rollout influence revenue forecasts?
Global regulatory approvals and reimbursement policies vary; North America and Europe remain primary markets impacting overall revenues.
References
[1] MarketWatch. (2023). Global age-related macular degeneration market forecast. Retrieved from https://www.marketwatch.com
[2] Grand View Research. (2022). Biosimilars Market Size, Share & Trends Analysis. Retrieved from https://www.grandviewresearch.com
[3] U.S. Food and Drug Administration. (2022). Biosimilar Development and Approval. Retrieved from https://www.fda.gov
[4] IQVIA. (2022). Biosimilar Market Insights. Retrieved from https://www.iqvia.com
[5] Novartis. (2022). Annual Report 2022. Retrieved from https://www.novartis.com
